Selected article for: "RNA interference and shrna express"
Author: Sliva, Katja; Schnierle, Barbara S
Title: Selective gene silencing by viral delivery of short hairpin RNA
  • Cord-id: zcxemcn4
  • Document date: 2010_9_21
    • ID: zcxemcn4
    Snippet: RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-stranded (ds) interfering RNA oligonucleotides (s
    Document: RNA interference (RNAi) technology has not only become a powerful tool for functional genomics, but also allows rapid drug target discovery and in vitro validation of these targets in cell culture. Furthermore, RNAi represents a promising novel therapeutic option for treating human diseases, in particular cancer. Selective gene silencing by RNAi can be achieved essentially by two nucleic acid based methods: i) cytoplasmic delivery of short double-stranded (ds) interfering RNA oligonucleotides (siRNA), where the gene silencing effect is only transient in nature, and possibly not suitable for all applications; or ii) nuclear delivery of gene expression cassettes that express short hairpin RNA (shRNA), which are processed like endogenous interfering RNA and lead to stable gene down-regulation. Both processes involve the use of nucleic acid based drugs, which are highly charged and do not cross cell membranes by free diffusion. Therefore, in vivo delivery of RNAi therapeutics must use technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. Viruses and the vectors derived from them carry out precisely this task and have become a major delivery system for shRNA. Here, we summarize and compare different currently used viral delivery systems, give examples of in vivo applications, and indicate trends for new developments, such as replicating viruses for shRNA delivery to cancer cells.

    Search related documents:
    Co phrase search for related documents
    • accessory protein and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
    • accessory protein and additional protein: 1, 2
    • acute respiratory syndrome and adenoviral vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and adenovirus contrast: 1, 2
    • acute respiratory syndrome and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory syndrome and administration mode: 1, 2, 3
    • acute respiratory syndrome and liver fibrosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome and liver toxicity: 1, 2, 3, 4
    • acute respiratory syndrome and local application: 1, 2, 3, 4, 5
    • acute respiratory syndrome and local injection: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and long double: 1, 2
    • acute respiratory syndrome and long term culture: 1, 2, 3
    • acute respiratory syndrome and long term expression: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and long terminal repeat: 1, 2
    • acute respiratory syndrome and low reactivity: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and ltr long terminal repeat: 1, 2
    • acute respiratory syndrome and lysosomal escape: 1
    • acute respiratory syndrome and macular degeneration: 1, 2, 3, 4, 5